Chemotherapy-induced myelosuppresion
Conditions
Interventions
Control group:Patients underwent platinum-based chemotherapy protocols or platinum-enhanced combination chemotherapy (with a 3-week cycle duration), complemented by standard oncology nursing care. Pre
FBR group:In addition to the standard treatment regimen for the control group, patients received FBR as a supplementary intervention. The FBR was meticulously prepared by the research team, adhering t
Sponsors
Nanjing Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
49 Years to 72 Years
Inclusion criteria
Inclusion criteria: ? Patients diagnosed with malignant tumors through clinical and laboratory examinations; ? Individuals aged between 18 and 85 years old with an expected survival period of =3 months; ? Patients with a Karnofsky Performance Status (KPS) scores =60 before chemotherapy; ? Patients scheduled to receive chemotherapy with platinum-based drugs, including oxaliplatin, cisplatin, carboplatin, nedaplatin, etc., or combination chemotherapy regimens based on platinum drugs; ? No history of food or drug allergies; ? Patients with ability to cooperate in completing survey questionnaires, provide regular follow-up data, and be followed up.
Exclusion criteria
Exclusion criteria: ? Special populations such as pregnant or lactating women, psychiatric patients; ? Halal or vegetarian individuals and those who personally object to consuming pig's trotters; ? Individuals with conditions such as gout, hyperlipidemia, or peptic ulcers, who should avoid purine-rich foods; ? Participants in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood parameters;adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome scores;KPS scores; | — |
Countries
China
Contacts
Public ContactGuihua Xu
Nanjing University of Chinese Medicine
Outcome results
None listed